Login to Your Account

Janssen taps Arcturus to help make HBV therapy, sending Alcobra shares higher

By Michael Fitzhugh
Staff Writer

Thursday, October 19, 2017

Janssen Pharmaceuticals Inc. is enlisting privately held RNA therapy specialist Arcturus Therapeutics Inc. to help it develop and commercialize new nucleic acid-based drugs for HBV and possibly other infectious and respiratory diseases.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription